RBC raises target for Regeneron stock from USD 737 to USD 810

Published on 10/12/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock costs EUR 668.00 on October 12, 2026. Q2 revenue reached USD 4.29 billion, up 16.70 percent year over year.

Key points in brief

RBC Capital raised its Regeneron price target from USD 737 to USD 810 on October 8, 2026, while keeping a Sector Perform rating.
Regeneron reported USD 4.29 billion in second-quarter 2026 revenue, up 16.70 percent year over year.
The stock was trading at EUR 668.00 at Lang & Schwarz on October 12, 2026 at 12:30:40 p.m. CEST.
Regeneron has scheduled ESMO presentations for October 23 through October 27, 2026, and quarterly results for October 30, 2026.

Makroaufnahme einer transparenten Antikörper-Proteinstruktur in Blau- und Weißtönen — Regeneron Pharma US75886F1075 fokussiert eine detailreiche Makroaufnahme einer transparenten Antikörper-Proteinstruktur mit feinen Lichtreflexen, Illustration mit AI erstellt.

Regeneron stock was trading at EUR 668.00 at Lang & Schwarz on October 12, 2026 at 12:30 p.m. CEST. The latest analyst move came on October 8, when Markets Insider reported that RBC Capital raised its Regeneron target from USD 737 to USD 810 and kept a Sector Perform rating.

Three dated developments shape the story

On October 1, Regeneron announced an expanded Sanofi alliance covering four long-acting antibodies. The agreement includes a USD 1.0 billion upfront payment and potential milestone payments of up to USD 7.0 billion.

On October 6, Regeneron announced 10 abstracts for the ESMO 2026 Congress, covering cancer, ovarian cancer and cancer-associated thrombosis. On October 8, RBC raised its target to USD 810 from USD 737, according to Markets Insider.

What anchors the next catalyst?

The near-term calendar is unusually concrete. Regeneron's ESMO presentations are scheduled for October 23 through October 27, 2026, with late-breaking Phase 3 C-POST survival data among the planned disclosures, according to the company's October 6 release.

The commercial backdrop is already measurable. Regeneron generated USD 4.29 billion of revenue in the second quarter of 2026, up 16.70 percent from the prior-year quarter, while net income reached USD 1.30 billion, according to Yahoo Finance. The comparison matters because the pipeline announcements are being assessed against an operating business that is still expanding.

Results date keeps attention high

Yahoo Finance lists October 30, 2026 as Regeneron's next earnings date. That report will give investors a fresh test of whether second-quarter revenue growth can offset continuing scrutiny around Eylea trends and support the valuation case behind the higher RBC target.

Regeneron had a market capitalization of USD 76.9 billion as of October 9, 2026, while its Nasdaq 52-week range was USD 541.00 to USD 859.34. The Lang & Schwarz price of EUR 668.00 therefore supplies the German-market reference, while the USD figures describe the primary listing separately.

Price and investor reference

At Lang & Schwarz, Regeneron was trading at EUR 668.00 on October 12, 2026 at 12:30 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.